Recent Updates
Recently added Catalysts
CGON Positive Sentiment

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Key Takeaway: CG Oncology, a late-stage clinical biopharmaceutical company, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. CEO Arthur Kuan will lead a fireside chat, highlighting the company's focus on bladder cancer therapies. The event will be accessible via a live audio webcast.
Price reaction · baseline $26.58 (2025-06-04 close) · hit pre-market · clean, no other CGON news in the window
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious healthcare conference
  • Opportunity to showcase innovative therapies for bladder cancer
  • Engagement with investors and stakeholders

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website atwww.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit:www.cgoncology.com.

Contacts:MediaSarah ConnorsVice President, Communications and Patient Advocacy, CG Oncology(508) 654-2277sarah.connors@cgoncology.com

Frequently Asked Questions

When will CG Oncology participate in the conference?

CG Oncology will participate in the conference on June 10, 2025.

Who will represent CG Oncology at the conference?

Arthur Kuan, the CEO, will represent CG Oncology at the conference.

How can I access the conference webcast?

The conference webcast can be accessed from the Investor Relations section of CG Oncology's website.

What is the focus of CG Oncology?

CG Oncology focuses on developing therapies for bladder cancer patients.

Last updated: Jun 5, 2025